

EPSRC

Future Vaccine Manufacturing Research Hub

Advancing the manufacture and deployment of cost effective vaccines



Future Vaccine Manufacturing Research Hub

- Introduction to the FVMR Hub
- Aims and objectives
- Hub capabilities and initiatives
- Current partners
- Opportunities for interaction, partnerships and proposals
- Discussion

Future Vaccine Manufacturing Research Hub

- Introduction to the FVMR Hub
- Aims and objectives
- Hub capabilities and initiatives
- Current partners
- Opportunities for interaction, partnerships and proposals
- Discussion

Future Vaccine Manufacturing Research Hub

Introduction to the Hub

- The new Future Vaccine Manufacturing Research Hub at Imperial College London, has been established with £10 million (GBP) of funding from the UK Department for Health, administered by EPSRC.
- Incorporates research groups across Imperial College experiences in vaccine R&D, process engineering and manufacturing
- Linked to additional UK spokes with experience in formulation, computational modelling, process development and vaccine QA/QC (NIBSC)
- Established developing country vaccine manufacturer spokes, initially in India, Vietnam, Bangladesh, Uganda and China
- Looking to expand collaboration with additional partners.

Future Vaccine Manufacturing Research Hub

- Introduction to the FVMR Hub
- **Aims and objectives**
- Hub capabilities and initiatives
- Current partners
- Opportunities for interaction, partnerships and proposals
- Discussion


Future Vaccine Manufacturing Research Hub

Aims and objectives

- We will adopt an integrated approach that will build on new developments in life sciences, immunology and engineering to address two key challenges
 - How to design production systems that can produce tens of thousands of new doses within weeks of a new threat being identified
 - How to improve the way vaccines are manufactured, stabilised and stored so that existing and new diseases can be prevented effectively, and costs reduced


Goal: advancing the manufacture and deployment of cost effective vaccines

Responsive to the treat of emerging and re-emerging infections



Responding to developing world vaccine needs

Copyright © The McGraw-Hill Companies, Inc. Permission required for reproduction or display.




Identifying gaps in technology transfer

- Research and Development capacity to support technology transfer, develop novel vaccines, work around existing IP
- Vaccine specific modelling – manufacture, distribution, markets
- Business case/sustainability to support adoption, adapt to changing markets, respond to supply and demand
- Know-how – workforce (training, expertise, retention)
- Know-how in emerging technology (when to adopt or drop)
- Know-how in process optimisation
- QA/QC and regulatory affairs for new technologies and ultimately pre-qualification


Opportunity: leap-frog existing investments by exploiting emerging platforms

New model for Technology Transfer

Bilateral technology transfer








Advanced Technology Hub




Engineering deliverables at multiple levels

- Replicon RNA vaccines
- Enhanced yeast expression platforms
- Insect cell-baculovirus expression system (IC- BEVS)
- Generalized Modules for Membrane Antigens (GMMA)
- Formulation for heat stabilisation
- Process optimisation of manufacturing platforms
- Vaccine specific modelling and decisional tools
- R&D training and support
- QA & QC support and training




Developing appropriate partnership



● Transfer of specific technology
 ——— Development with Hub support
 ----- Self development

Future Vaccine Manufacturing Research Hub

- Introduction to the FVMR Hub
- Aims and objectives
- **Hub capabilities and initiatives**
- Current partners
- Opportunities
- Discussion



1. Provision of QA/QC support and training


- Development of QA assays for novel manufacturing platforms
- Provision of vaccine potency assays for viral and bacterial vaccines
- Development of validated assays and reference materials for emerging infections
- Advice on manufacturing QA and regulatory approval underpinning prequalification



2. Provision of vaccine specific modelling and decisional tools


- Objectives:
 - operational efficiency for cost reduction
 - rapid response of existing assets
 - end-to-end system design
- Whole process analysis and optimisation to address bottlenecks
 - In Life Sciences: host cell system or vector optimisation for improved productivity/quality
 - In Engineering: downstream separations, formulation and packaging
 - Established computational platform for modelling and optimising vaccine manufacturing processes to reduce costs

Multi-scale modelling capabilities



Current capabilities within the hub


- We have established a computational platform for modelling and optimising vaccine manufacturing processes to reduce costs
- Apply whole process optimisation, system design and process intensification to improve operational flexibility and efficiency
- Process intensification has great promise for cost reduction and improvement of responsiveness in vaccine manufacturing
- Optimise using process mapping, bottleneck identification and process intensification, building on work in biologics manufacturing .
- Deliverable: Demonstration of benefits of integrated approach on primary production systems



Downstream separations typically incur significant costs and in-process times


Exemplar purification concepts

- “process telescoping” whereby several unit operations are combined into one (e.g. expanded bed affinity adsorption combining solids removal, capture and primary purification)
- continuous operation (e.g. moving to continuous chromatography using simulated moving bed technology).
- Our key activities will involve high throughput experiments, models and big data analytics.
- Deliverable: Demonstration of new vaccine separation design concepts at lab scale




Computational models for whole systems analysis


- Multi-scale modelling of biological processes through to unit operation and whole value chains will be used for system analysis, design and manufacturing operation optimisation
- How do parameters characterising single unit performance e.g. titre, purity, recovery, formulation recipe influence whole system metrics e.g. cost per dose, lead times?



3. Process optimisation of emerging manufacturing platforms: Industrialisation, demonstration, deployment




Process concepts



Manufacturing
Engineering
Design
Optimisation



10 platform designs ("blueprints")





6 physical demonstrators at LMIC sites

Scale up and industrialisation analysis;
Value chain modelling and economic analysis, decision making tools
Builds on existing experience in optimising industrial processes

4. Formulation for heat stabilisation

- Advanced freeze-drying formulations and processes for vaccine stabilisation ≥ 6 months
- Generation of highly thermally-stable liquid vaccine formulations
 - (biocompatible ionic liquids, 40 °C for 12 months)
- Novel vaccine delivery formulations providing dose sparing and enhanced immunogenicity
- Wider exploitation of disposable pouch system for oral vaccine delivery



Centralised versus decentralised manufacture



Single manufacturing plant

- Economies of scale and volume
- Hundreds of millions of doses
- Standardised QC/QA
- Applicable to complex manufacture (pneumococcal conjugate vaccine)
- Global distribution
- High up front capital costs
- High personnel costs
- Low flexibility

A toolbox of technologies, training, methodologies, and material designed to meet common needs among emerging vaccine manufacturers



Central Hub

- Up to millions of doses
- National/regional
- Neglected diseases
- Rapid response to emerging and local infections
- High flexibility


- Staff/training
- QMS
- Equipment
- Consumables
- QA/QC testing





Seed technology to any number of LMIC facilities capable of cGMP, fill/finish labelling

Enhanced delivery: formulation, route, supply chain...

Identifying core platforms for further exploitation



Exploitation of the multiBac Platform





Baculovirus expression vector system (BEVS)

Engineering enhanced yeast based expression platforms

Secretory Pathway Engineering:

- Upregulate UPR
- Expand ER size
- 'bgs' modifications




Industrial fermentation

A number of individual strain modifications have been identified

We aim to combine these to create a “super-strain” and re-engineer human glycosylation


Ensure bioprocess optimisation

Generalized Modules for Membrane Antigens (GMMA)




F. Micoli | GMMA technology

- GMMA are released yielding pure source of outer membrane
 - Similar size to virus-like particles
 - Contain PAMPs: naturally adjuvanting
 - Multiple antigens are presented in their natural environment and conformation



- Genetic modifications trick bacteria into shedding outer membranes




Eleonora Meloni & Taddei Anna Rita C.I.M.E. Institute, Università della Toscana

GSK Vaccines Institute for Global Health (GVGH)


Self-amplifying RNA based vaccines

B: Self-amplifying RNA




Legend


- Antigen gene
 - Antigen protein
 - Replicase gene
 - Replicase protein
 C - CAP
 - Genomic promoter
 - Subgenomic promoter




In vitro transcription
with T7 polymerase



DNase digestion of
DNA template



RNA capping



Protein digestion
with Proteinase K



Purification

Fully synthetic, small foot-print, low-cost rapid manufacture

Future Vaccine Manufacturing Research Hub

- Introduction to the FVMR Hub
- Aims and objectives
- Hub capabilities and initiatives
- **Current partners**
- Opportunities for interaction, partnerships and proposals
- Discussion


Current LMIC partnerships



- Hilleman Laboratories, India
 - development of a thermostable combined oral Cholera-ETEC vaccine
- Dalian Hissen, China
 - development of robust, modular and intensified manufacturing process capable of enhancing and accelerating yeast based production
- Incepta Pharmaceuticals, Bangladesh
 - production of formulated pilot vaccines using novel therostable stable formulations and demonstration of thermal stability and therefore the lifetime of the formulation
- Vabiotech, Vietnam
 - Establishment of a modular platform for IC-BEVS production in Vietnam
- UVRI, Uganda
 - Establishment of a modular platform for RNA production in Uganda

Future Vaccine Manufacturing Hub


Process innovation



- NIBSC
- CPI, Darlington
- NHSBT CBC, Bristol

- GSK (Global Health)
- Dalian Hissen, China
- Incepta Pharmaceuticals, Bangladesh
- Vabiotech, Vietnam

Advanced Technology Hub



- Hilleman Laboratories – India
- UVRI, Uganda


- Cambridge
- Nottingham
- Bristol
- Cranfield

Manufacturers

Manufacturers

Manufacturers


Developing Countries Vaccine Manufacturers Network




VLPs




RNA




Yeast



IC-BEVS



GMMA



Future Vaccine Manufacturing Research Hub

- Introduction to the FVMR Hub
- Aims and objectives
- Hub capabilities and initiatives
- Current partners
- Opportunities for interaction, partnerships and proposals
- Discussion

Opportunities for interactions & partnerships

- QA & QC support and training
- R&D training and support
- Access to Vaccine specific modelling and decisional tools
- Collaboration on process optimisation of manufacturing platforms
- Partnerships on formulation for heat stabilisation
- Partnerships on vaccine platform development
- Leveraging of existing investment to attract additional funding

Proposals



- *LMIC R&D and technology transfer flexible fund (£400,000)*
- Vaccine Hub to present, together with members at the pre-meeting symposium
- DCVMN likely to serve as platform for small grants (applications/management /reporting)
- Will provide consulting expertise for members to advance with GMP, process optimization, regulatory dossiers, PQ, investments, and partnerships with the Hub

Future Vaccine Manufacturing Research Hub

- Introduction to the FVMR Hub
- Aims and objectives
- Hub capabilities and initiatives
- Current partners
- Opportunities for interaction, partnerships and proposals
- **Discussion**

Thank you for your attention

Contact: r.shattock@ic.ac.uk